



(11) **EP 2 425 850 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:  
**Corrected version no 1 (W1 A2)**  
**Corrections, see**  
**Bibliography INID code(s) 22**

(51) Int Cl.:  
**A61K 39/395** *(2006.01)* **C07K 16/44** *(2006.01)*  
**C07K 16/28** *(2006.01)*

(48) Corrigendum issued on:  
**25.04.2012 Bulletin 2012/17**

(43) Date of publication:  
**07.03.2012 Bulletin 2012/10**

(21) Application number: **11177829.6**

(22) Date of filing: **14.06.2006**

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI  
SK TR**

(30) Priority: **15.06.2005 US 154103**

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
**06784990.1 / 1 912 674**

(71) Applicants:  
• **The Regents of The University of California  
Oakland, CA 94607-5200 (US)**  
• **FOX CHASE CANCER CENTER  
Philadelphia, PA 19111 (US)**

(72) Inventors:  
• **Adams, Gregory P.  
Philadelphia, PA 19111 (US)**

• **Horak, Eva M.  
West Orange, NJ 07052 (US)**  
• **Weiner, Louis M.  
Washington DC 20016 (US)**  
• **Marks, James D.  
Kensington, CA 94707 (US)**

(74) Representative: **Turner, Rhiannon Rosalind  
Greaves Brewster LLP  
Copa House  
Station Road  
Cheddar, BS27 3AH (GB)**

Remarks:  
This application was filed on 17-08-2011 as a  
divisional application to the application mentioned  
under INID code 62.

(54) **Bispecific single chain FV antibody molecules and methods of use thereof**

(57) Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.

**EP 2 425 850 A8**